Abstract:The receptor tyrosine kinase AXL is overexpressed in many cancer types including thyroid carcinomas and has well established roles in tumor formation and progression. Proper folding, maturation, and activity of several oncogenic receptor tyrosine kinases require HSP90 chaperoning. HSP90 inhibition by the antibiotic geldanamycin or its derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) causes destabilization of its client proteins. Here we show that AXL is a novel client protein of HSP90. 17-AAG induced a time- and dose-dependent down-regulation of endogenous or ectopically expressed AXL protein, thereby inhibiting AXL-mediated signaling and biological activity. 17-AAG-induced AXL down-regulation specifically affected fully glycosylated mature receptor present on cell membrane. By using biotin and [(35)S]methionine labeling, we showed that 17-AAG caused depletion of membrane-localized AXL by mediating its degradation in the intracellular compartment, thus restricting its exposure on the cell surface. 17-AAG induced AXL polyubiquitination and subsequent proteasomal degradation; under basal conditions, AXL co-immunoprecipitated with HSP90. Upon 17-AAG treatment, AXL associated with the co-chaperone HSP70 and the ubiquitin E3 ligase carboxyl terminus of HSC70-interacting protein (CHIP). Overexpression of CHIP, but not of the inactive mutant CHIP K30A, induced accumulation of AXL polyubiquitinated species upon 17-AAG treatment. The sensitivity of AXL to 17-AAG required its intracellular domain because an AXL intracellular domain-deleted mutant was insensitive to the compound. Active AXL and kinase-dead AXL were similarly sensitive to 17-AAG, implying that 17-AAG sensitivity does not require receptor phosphorylation. Overall our data elucidate the molecular basis of AXL down-regulation by HSP90 inhibitors and suggest that HSP90 inhibition in anticancer therapy can exert its effect through inhibition of multiple kinases including AXL.

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells

HSP90 Inhibitor, 17-AAG, Inhibits Invasion of ATC by Down-Regulating HIF-1α

The HSP90 Inhibitor 17-PAG Effectively Inhibits the Proliferation and Migration of Androgen-Independent Prostate Cancer Cells

Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor

Design, Synthesis and Biological Evaluation of 17-Arylmethylamine-17-demethoxygeldanamycin Derivatives As Potent Hsp90 Inhibitors

Effect of HSP90 Inhibitor in Pheochromocytoma PC12 Cells: an Experimental Investigation

Effects of 17-Allylamino-17-demethoxygeldanamycin on Apoptosis and Expression of Vascular Endothelial Growth Factor in Pheochromocytoma Cells

Influence of 17AAG on proliferation and invasion of gastric cancer cell and its mechanism

Inhibitory effect of 17AAG on proliferation and invasion of hepatocellular carcinoma cells

HSP27 Expression Levels Are Associated with the Sensitivity of Hepatocellular Carcinoma Cells to 17-Allylamino-17-demethoxygeldanamycin.

SNX-25a, a Novel Hsp90 Inhibitor, Inhibited Human Cancer Growth More Potently Than 17-AAG.

Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation

Effect Of Hsp90 Inhibitor On Proliferation Of Leukemia Cells And Mechanism Of Inducing Apoptosis

The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model

[Proliferation and Apoptosis of Leukemia Cell Line K562 Treated with HSP90 Inhibitor 17-DMAG].

Geldanamycin, a Heat Shock Protein 90‐binding Agent, Disrupts Stat5 Activation in IL‐2‐stimulated Cells

17-Abag, A Novel Geldanamycin Derivative, Inhibits Lncap-Cell Proliferation Through Heat Shock Protein 90 Inhibition

HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma

In Vitro and in Vivo Evaluation of 17-Phenylpropylamine/phenoxyethylamine-17-demethoxygeldanamycins As Potent Hsp90 Inhibitors

17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration

17-DMCHAG, a New Geldanamycin Derivative, Inhibits Prostate Cancer Cells Through Hsp90 Inhibition and Survivin Downregulation